References
- Aida, T., Kimura, T., Ishikawa, N., and Shinkai, K. (1998). Evaluation of allergenic potential of low-molecular compounds by mouse popliteal lymph node assay. J. Toxicol. Sci. 23:425–432
- Aihara, M. (2011). Pharmacogenetics of cutaneous adverse drug reactions. J. Dermatol. 38:246–254
- Albers, R., Broeders, A., van der Pijl, A., et al. (1997). The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Toxicol. Appl. Pharmacol. 143:102–109
- Cheng, L., Sterwart, B. J., You, Q., et al. (2008). Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo. Mol. Pharmacol. 73:1769–1775
- Depta, J. P., Altznauer, F., Gamerdinger, K., et al. (2004). Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J. Allergy Clin. Immunol. 113:519–527
- Faulkner, L., Martinsoon, K., Santoyo-Castelazo, A., et al. (2012). The development of in vitro culture methods to characterize primary T-cell responses to drugs. Toxicol. Sci. 127:150–158
- Gleichmann, H. (1981). Studies on the mechanism of drug sensitization: T-cell-dependent popliteal lymph node reaction to diphenylhydantoin. Clin. Immunol. Immunopathol. 18:203–211
- Gomes, E. R., and Demoly, P. (2005). Epidemiology of hypersensitivity drug reactions. Curr. Opin. Allergy Clin. Immunol. 5:309–316
- Hanley, J. A., and McNeil, B. J. (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36
- Illing, P. T., Vivian, J. P., Dudek, N. L., et al. (2012). Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486:554–558
- Ko, T. M., Chung, W. H., Wei, C. Y., et al. (2011). Shared and restricted T-cell receptor use is crucial for carbamazepine-induce Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 128:1266–1276
- Kwast, L. M., Fiechter, D., Hassing, I., et al. (2011). Oral exposure to drugs with immune-adjuvant potential induces hypersensitivity responses to the reporter antigen TNP-OVA. Toxicol. Sci. 121:312–319
- Lavergne, S. N., Wang, H., Callan, H. E., et al. (2009). “Danger” conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J. Pharmacol. Exp. Ther. 331:372–381
- McLeod, A. I., and Bellhouse, D. R. (1983). A convenient algorithm for drawing a simple random sample. Appl. Stats. 32:182–183
- Norcross, M. A., Luo, S., Lu, L., et al. (2012). Abacavir induces loading of novel self-peptides into HLA-B*57: 01: An autoimmune model for HLA-associated drug hypersensitivity. AIDS 26:F21–29
- Ostrov, D. A., Grant, B. J., Pompeu, Y. A., et al. (2012). Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc. Natl. Acad. Sci. USA 109:9959–9964
- Ozcan, D., Seckin, D., Bilezicki, B., and Arlslan, H. (2010). The role of human herpesvirus-6, Epstein-Barr virus and cytomegalovirus infections in the etiopathogenesis of different types of cutaneous drug reactions. Int. J. Dermatol. 49:1250–1254
- Pieters, R. (2001). The popliteal lymph node assay: A tool for predicting drug allergies. Toxicology 158:65–69
- Ravel, G., and Descotes, J. (2005). Popliteal lymph node assay: Facts and perspectives. J. Appl. Toxicol. 25:451–458
- Shinkai, K., Nakamura, K., Tsutsui, N., et al. (1999). Mouse popliteal lymph node assay for assessment of allergic and autoimmunity-inducing potentials of low-molecular-weight drugs. J. Toxicol. Sci. 24:95–102
- Thong, B. Y., and Tan, T. C. (2011). Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 71:684–700
- Weaver, J. L., Chapdelaine, J. M., Descotes, J., et al. (2005). Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions. J. Immunotoxicol. 2:11–20
- Wei, C. Y., Ko, T. M., Shen, C. Y., and Chen, Y. T. (2012). A recent update of pharmacogenomics in drug-induced severe skin reactions. Drug Metab. Pharmacokinet. 27:132–141